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Objective: Alleviation of cerebral oedema, not to correct 
sodium. Therefore, provision is only to severely 
symptomatic patients.  
Place and Duration of Study: This study was carried 
out from Jan 2018 to March 2018 at Mayo Hospital, 
Lahore, Pakistan.  
Materials and Methods: Out of 3000 patients, 
100(3.3%) patients had hyponatremia defined as having 
level of serum sodium less than 135mmol/L. Among 
them male patients were 65(65%) and female patients 
were 35(35%) with average 55 years of age. 
Results: In 24(22.2%) patients severe hyponatremia 
(Na+ < 120 mmol/L) was detected. Euvolemic was the 
largest group of hyponatraemic patients with 42(42%), 
then hypervolemic patients with 33(33%) and thirdly 
hypovolemia patients with 25(25%). 4(4%) patients out 
of 100 patients qualify the criteria for Syndrome of 
Inappropriate Anti Diuretic Hormone (SIADH). During 
stay at hospital, 2(2%) out of 100 hyponatraemic patients 
died. No death was secondary to hyponatremia. No 
patient was Tolvaptan (a V2RA) and only 3(3%) patients 
out of 100 were given saline. At the time of discharge, 
73(73%) patients out of 100 were having serum sodium 
level more than135 mmol/L. 
Conclusion:Among the hospitalised patients of Pakistan, 
hyponatremia is common. The most common type was 
euvolemic hyponatremia, a good amount of them was 
secondary to SIADH. It isa challenge to manage 
hyponatremia but mostly inpatients we managed 
hyponatremia in spite of unavailability of 3% saline or 
V2 receptor antagonist.  
Key Words: Hyponatremia,Euvolemic, Syndrome 
of Inappropriate Anti-Diuretic Hormone Secretion 
INTRODUCTION  
The presence of hyponatremia in hospitalised 
patients is quite common across the world. The 
prevalence differs in various researches and it 
ranges from 5% to 30%. The aetiology is also 
different in other clinical settings and number of 
patients. Mostly in studies, SIADH and euvolemic 
hyponatremia is the most frequent cause in 
hospitalised patients. Hyponatremia management 
has always challenged nephrologists and clinicians. 
Fresher agents are modifying the mode of 
hyponatremia management. In Pakistan, the 
management in hospitalised patients is becoming 
more difficult because of dearth of hypertonic 
saline and absence of V2 receptor antagonist. No 
information relating to hyponatremia prevalence, 
management and aetiology in hospitalised patients 
is available.  
Cross-sectional study was carried out in a private 
hospital based in Lahore for determining the 
aetiological element, prevalence and hyponatremia 
management. The literature was reviewed for 
discussing the available choices for managing the 
various kinds and degrees of hyponatremia in 
patients hospitalised.  
MATERIALS AND METHODS 
The patients with serum sodium (Na+) level less 
than 135 mmol/L (normal range 145 to 45 mmol/L) 
were made part of the studycarried out from Jan 
2018 to March 2018 at Mayo Hospital, Lahore, 
Pakistan. Patients were also included who 
werehaving history of chronic hyponatremia or had 
hyponatremia during earlier hospitalisation. The 
report of 1st admission serum electrolyte was 
considered for criteria of inclusion. The patients 
were also included in whom the hyponatremia 
developed during hospitalisation. All patients were 
excluded having pseudo hyponatremia (secondary 
to Hyperproteinaemia &Hyperlipidaemia) or 
hyponatremia secondary to hyperglycaemiaor 
mannitol were excluded therefore including pure 
patients of hyponatraemic patients only.In order to 
diagnose different hyponatremia aetiology, the 
standard diagnostic criteria were used. The volume 
status of the patients was measured clinically as 
euvolemic, hypervolemic and hypovolemic.  
Suspected patients of pseudohyponatremia were 
not included in the research and only pure patients 
of hyponatremia were added. Laboratory tests were 
performed in hyponatremia patients such as 
complete blood count, serum electrolytes, serum 
creatine, renal function test including blood urea 
nitrogen, thyroid function test, serum uric acid, 
serum cortisole, random urine sodium, serum 
osmolality, urine complete, random urine 
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osmolality and chest x-rays. In selected cases 
ultrasound KUB, serum BNP and 2D 
Echocardiogram were performed.  The normal 
range in hospital laboratory (Chughtai’s Lab) of 
serum sodium is 135 to 145 meq/l, urine osmolality 
is 500–850 mosm/kg water and serum osmolality is 
275–293 mosm/kg of water. severe hyponatremia 
defined as serum Na+ < 120 meq/l and normal 
Hyponatremia is defined as Na+ < 135 meq/l. As 
per need the consultation of cardiology, 
endocrinology and nephrology were requested. For 
the purpose of exclusion SIADH is diagnosed and 
Bartter-Schwartz have defined the classic criteria 
that can be summed up as;  
1. Hyponatremia with corresponding hypo-
osmolality 
2. Urine less than maximally dilute 
3. Continued renal excretion of sodium 
4. Absence of other causes of hyponatremia 
5. Absence of clinical evidence of volume 
depletion  
6. Correction of hyponatremia by fluid 
restriction 
Management of the patients was based on the 
standard guidelines. The patient was considered as 
chronic hyponatremia if he was having 
hyponatremia for more than 48 hours or for 
unknown duration. Sodium was not enhanced more 
than 10 to 12 meqin chronic hyponatremia during 
the 1st 24 hours in order to avoid central pontine 
myelinolysis. Hyponatremia acute had been 
defined as development of level of low serum 
sodium within last 48 hours. Demeclocycline, 
hypertonic saline and tolvaptan were unavailable. 
The management of hyponatremia was performed 
by treating basic reasons, oral salt tablets, water 
restriction, normal saline with or without sodium 
bicarbonate and furosemide in different 
combinations. Hypertonic saline was given to only 
4 patients having severe symptomatic 
hyponatremia 3 of them having serum sodium 105, 
109 & 110 mmol/L and the 4th one has less than 
100 mmol/L. The arrangement of hypertonic saline 
is not an easy task normally it is arranged by the 
family.  
RESULTS  
Out of 3000 patients hospitalised, 100(3.3%) 
patients had hyponatremia defined as having level 
of serum sodium less than 135mmol/L. Among 
them male patients were 65(65%) and female 
patients were 35(35%) with average 55 years of 
age. Out of 100 patients, 27(27%) were having the 
serum sodium level less than 120. Mostly patients 
having mild hyponatremia preventing the causative 
drug or the treatment of basic causes along with 
water restriction fixed sodium. In hypovolemia 
patients, correction of fluid loss by hyponatremia 
with normal saline assisted correct serum sodium. 
The hyponatremia causes are as follow:  
3 patients having adrenal insufficiency and 
hypothyroidism were given thyroxin and steroids to 
correct sodium. Patient having basic polydipsia was 
advised to avoid fluid and it corrected sodium. But 
after two weeks with hyponatremia secondary to 
bad compliance with fluid the patient was again 
hospitalised and was referred to psychiatry. The 
management of hyponatremia secondary to 
idiopathic SIADH, congestive heart failure (CHF), 
chronic live diseased (CLD)was the most difficult. 
In spite of the use of furosemide, the level of serum 
sodium remains 128 to 136 in patients. 4 severe 
hyponatremia patients (having serum sodium less 
than 100,105,109 and 110 mmol/L) required about 
one litre of 3% saline to correct sodium and causes 
to take sodium at secure range of 115 to 120 
mmol/L. Mostly patients respond to normal saline 
with sodium bicarbonate for the creation of 
hypertonic IV fluid (tonicity 1.5 to 2.5%). The 
bicarbonate solution was particularly used for 
patients having some level of metabolic acidosis. 
The preparation of fluid is based on the 
nephrologist’s recommendation depending on the 
level of serum bicarbonate, sodium and require 
correcting sodium. There was low sodium of 
unclear aetiology in ourpatients, but they responded 
to hold pregabalin. Physician restarted pregabalin 
and returned to OPD with low sodium level of 121 
that again responded to hold pregabalin. No 
complication was developed in patients resulting 
from hyponatremia or its treatment. Patients mostly 
were managed in general ward with an exception of 
few patients having severe and acute hyponatremia 
which need to be managed in ICU. Around 50% 
patient were lost for the purpose of follow up but 
mostly patients had level of serum sodium in 
normal range with few exceptions of chronic liver 
disease, advance congestive heart failure and 
idiopathic Syndrome of Inappropriate Anti-Diuretic 
Hormone. 
DISCUSSION  
The presence of hyponatremia in a group of 
hospitalised patients was 3.3%. In other 
epidemiological researches the prevalence has been 
shown between 5 to 30% in different clinical 
settings depending on various aetiological risk 
element. In the current research, the level of 
hyponatremia prevalence is less as compared to 
values reported in mostly western literature. Slight 
low occurrence be considered as secondary to the 
fact that the study involved all patients inclusion of 
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surgical, obstetrics and gynaecology, medical and 
hospitalised for limited period. otherwise mostly 
patients were healthy and for short period 
hospitalisation for delivery of new born or elective 
surgery or for procedure such as angiogram to 
exclude acute coronary syndrome etc. Recently, the 
prevalence of 4.7% has been reported by Sandar 
Win, Komal Patel, Maria V De Vita et al. in the 
patients hospitalised. The prevalence of 4.2% 
according to current data is in consistent with the 
prevalence reported by them. In the hyponatremia 
aetiological terms, it has been found that likewise 
others, SIADH is the most frequent cause of 
hyponatremia in patients. Chronic liver disease is 
also common reason of hyponatremia. Perhaps this 
would be secondary to the fact that in Pakistan and 
South East Asia there is prevalence of hepatitis 
B&C, chronic liver disease and cirrhosis. The 
findings of the current research are in line with 
other researches with respect to the elements of 
aetiology. Hyponatremia management is still a 
challenge and requires good knowledge, 
pharmacological measures, non-pharmacological, 
multi-disciplinary approach and hypertonic saline 
availability, vasopressin receptor antagonist etc. 
hyponatremia in patient has been connected with 
high morbidity and mortality but the question is 
whether mortality is connected itself with 
hyponatremia or there are some underlying 
diseases which remains unclear. The assessment of 
the volume status of the patient is imperative in 
evaluating the type of hyponatremia that would 
assist in finding what type of management is 
needed. More fast correction by using of 
hypertonic saline may be needed if the patient 
hasserious hyponatremia symptoms (for example 
seizures) in order to avoid complications and 
cerebral oedema. Treatment of patients having 
severe hyponatremia may be challenging and 
difficult as the tolvaptan is unavailable and 
hypertonic saline is not available freely. All the 
patients were managed except few who needed 3% 
saline. After literature review and while relying on 
the experience these are the possible 
recommendation. Underlying cause treatment: 
stopping of diuretics such as selective serotonin 
uptake blockers hydrochlorothiazide and other 
likely drugs. Treatment of hyponatremia 
underlying correctable cause. Water restriction: it 
works in all circumstances and it must be 1st 
recommendation regardless of aetiology. Among 
the patients it works as wonder with primary 
polydipsia. The water restriction can be assessed 
relying on the patient’s urine osmolality, level of 
sodium and current water consumption. Normally 
the daily fluid restriction is 1 to 1.5 Litre.  
Salt Intake: it can be used to increase the level of 
serum sodium. There should be removal of salt 
restriction and salt can freely be used in diet. The 
use of salt (NaCl) can be in form of tablets or 
capsules. Every single tablet or capsule has 
normally 500mg of salt. There is need to monitor 
closely the volume status and blood pressure. Oral 
rehydrating solution must not be used unless 
potassium is low because it gives increased 
contents of potassium. Normal Saline: mostly the 
offered treatmentto hypovolemic hyponatremia 
patients is replacement of both water and salt by 
way of intravenous infusion of salt solutions. 
Unless there is obvious proof of dehydration and 
hypovolemia, the normal or hypotonic fluids must 
be evaded. It may result in worse hypervolemic 
hyponatremia. In case of Syndrome of 
Inappropriate Anti-Diuretic Hormone, the normal 
use of saline is dependent on urine osmolality 
which is normally fixed. Hyponatremia may be 
corrected by the assistance of urine osmolality if it 
is less than 308 mmol/L. if the urine osmolality is 
over 308 (normally over 450 mOsm/kg H2O in 
Syndrome of Inappropriate Anti-Diuretic 
Hormone) then hypotonic or normal saline would 
worsen the hyponatremia because of fixed urine 
osmolality and retention of free water after 
excretion of urine at increased osmolality. Sodium 
bicarbonate addition can support in enhancing the 
solution tonicity and it would assist in correcting 
hyponatremia. Furosemide can be of assistance for 
normal saline to rapidly improvise hyponatremia 
by dumping more water in urine as damage is 
caused by furosemide to renal tubular 
responsiveness to ADH. 
Demeclocycline: recommendation in case of 
Syndrome of Inappropriate Anti-Diuretic Hormone 
has been made but did not prove fruitful secondary 
to poor efficacy and side effects. In all analysis the 
demeclocycline effects are not significant and there 
is decline in its role because of the invention of 
new V2 receptor antagonists such as tolvaptans. 
Furthermore, it is unavailable in Pakistan. 
Hypertonic saline:  it is quite useful in case 
ofsevere symptoms and acute hyponatremia need to 
be promptly corrected. Centres such as Shifa, SIUT 
and Shaukat Khanum are preparing 3% saline but it 
cannot be found free from the pharmacies. With 
respect to replacement, required deficit of sodium 
can be assessed with the use of the formula. Na+ 
(mEq given as 3%) = (Na+ desired) – (Na+ 
measured) X estimated TBW. By this way the 
sodium amount in mEq can be given as 3% saline 
over time t. in 1 litre of 3% saline there are 513 
mEq of sodium. The determination of hypertonic 
saline volume to be given over time t, divide the 
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No. of sodium mEq to be given by 513 mEq/L. 
thereafter give the volume over time t. the efficacy 
of 3% saline can be enhanced by the addition of 
Lasix. 
The patient having sodium serum of 105 and 
pointed neurological signs of changed mental 
status, hypertonic saline is decided (3% saline, 
OSM=1026) must be given primarily with respect 
to the pointed hyponatremia and neurological signs. 
That’s the method of assessing the wanted sodium 
increase of 15 mmol/L during first thirty hours. 
Na+ deficit = 0.6 × 70 × (120-105), = 630 meq 
=1200mL of 3% saline At 40 ml/h over 30 h to 
raise the plasma Na+ concentration by 0.5 meq/L/h. 
sodium is enhanced by 6 to 8 meq/L with normally 
50 to 100 ml/hr for 4 to 6 hours which is normally 
sufficient for the reduction of signs severely V2 
Receptor Antagonist: in USA the oral Tolvaptan is 
available easily and is recommended and approved 
for hyponatremia management secondary to 
chronic liver disease , Syndrome of Inappropriate 
Anti-Diuretic Hormone and congestive heart 
failure. Canada is the exclusive country for the 
availability of Tolvaptan, the only V2R antagonist. 
A 4-years research of salt trials is recognised as 
Saltwater, it has been revealed that rise in the level 
of sodium serum was maintained for long time. 
Unluckily there is no availability of tolvaptan is in 
Pakistan. But whenever subject to availability of 
dose it should be started from 15 mg and can use 
maximum dose of 60 mg daily as required. During 
the use of tolvaptan, fluids or water are un-
restricted to evade fast correction of sodium. It is 
resulting in free water loss or aquaresis by stopping 
ADH receptor. It is pointed out and FDA has 
approved for hyponatremia because of Syndrome 
of Inappropriate Anti-Diuretic Hormone, Chronic 
liver disease or cirrhosis and congestive heart 
failure when aquaresis relatively diuresis is 
required because of hyponatremia. By the retention 
of sodium and resulting free loss of water, it 
corrects sodiumand give treatment to overload fluid 
particularly in chronic liver disease and congestive 
heart failure.  
CONCLUSION 
Hyponatremia is commonly found in Pakistani 
hospitalised patients. The most common type is 
euvolemic hyponatremia, a great number of which 
was secondary to Syndrome of Inappropriate Anti-
Diuretic Hormone. There is a challenge to manage 
hyponatremiabut hyponatremia is managed in 
mostly current patient in spite of unavailability of 
3% saline or V2 receptor antagonist.  
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